114 related articles for article (PubMed ID: 10801494)
21. Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite.
Nienaber V; Wang J; Davidson D; Henkin J
J Biol Chem; 2000 Mar; 275(10):7239-48. PubMed ID: 10702294
[TBL] [Abstract][Full Text] [Related]
22. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator.
Spraggon G; Phillips C; Nowak UK; Ponting CP; Saunders D; Dobson CM; Stuart DI; Jones EY
Structure; 1995 Jul; 3(7):681-91. PubMed ID: 8591045
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel inhibitors of urokinase via NMR-based screening.
Hajduk PJ; Boyd S; Nettesheim D; Nienaber V; Severin J; Smith R; Davidson D; Rockway T; Fesik SW
J Med Chem; 2000 Oct; 43(21):3862-6. PubMed ID: 11052791
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.
Kromann-Hansen T; Louise Lange E; Peter Sørensen H; Hassanzadeh-Ghassabeh G; Huang M; Jensen JK; Muyldermans S; Declerck PJ; Komives EA; Andreasen PA
Sci Rep; 2017 Jun; 7(1):3385. PubMed ID: 28611361
[TBL] [Abstract][Full Text] [Related]
25. Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase.
Renatus M; Bode W; Huber R; Stürzebecher J; Stubbs MT
J Med Chem; 1998 Dec; 41(27):5445-56. PubMed ID: 9876114
[TBL] [Abstract][Full Text] [Related]
26. Bicyclic peptide inhibitor reveals large contact interface with a protease target.
Angelini A; Cendron L; Chen S; Touati J; Winter G; Zanotti G; Heinis C
ACS Chem Biol; 2012 May; 7(5):817-21. PubMed ID: 22304751
[TBL] [Abstract][Full Text] [Related]
27. Probing inhibitors binding to human urokinase crystals by Raman microscopy: implications for compound screening.
Dong J; Swift K; Matayoshi E; Nienaber VL; Weitzberg M; Rockway T; Carey PR
Biochemistry; 2001 Aug; 40(33):9751-7. PubMed ID: 11502168
[TBL] [Abstract][Full Text] [Related]
28. Geometry of GPPE binding to picrate and to the urokinase type plasminogen activator.
Zesławska E; Stürzebecher J; Oleksyn BJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6212-5. PubMed ID: 17905583
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA).
Venkatraj M; Messagie J; Joossens J; Lambeir AM; Haemers A; Van der Veken P; Augustyns K
Bioorg Med Chem; 2012 Feb; 20(4):1557-68. PubMed ID: 22285569
[TBL] [Abstract][Full Text] [Related]
30. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
[TBL] [Abstract][Full Text] [Related]
31. The molecular basis of urokinase inhibition: from the nonempirical analysis of intermolecular interactions to the prediction of binding affinity.
Grzywa R; Dyguda-Kazimierowicz E; Sieńczyk M; Feliks M; Sokalski WA; Oleksyszyn J
J Mol Model; 2007 Jul; 13(6-7):677-83. PubMed ID: 17587094
[TBL] [Abstract][Full Text] [Related]
32. Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa.
Verner E; Katz BA; Spencer JR; Allen D; Hataye J; Hruzewicz W; Hui HC; Kolesnikov A; Li Y; Luong C; Martelli A; Radika K; Rai R; She M; Shrader W; Sprengeler PA; Trapp S; Wang J; Young WB; Mackman RL
J Med Chem; 2001 Aug; 44(17):2753-71. PubMed ID: 11495587
[TBL] [Abstract][Full Text] [Related]
33. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.
Frederickson M; Callaghan O; Chessari G; Congreve M; Cowan SR; Matthews JE; McMenamin R; Smith DM; Vinković M; Wallis NG
J Med Chem; 2008 Jan; 51(2):183-6. PubMed ID: 18163548
[TBL] [Abstract][Full Text] [Related]
34. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
35. Structure of human urokinase plasminogen activator in complex with its receptor.
Huai Q; Mazar AP; Kuo A; Parry GC; Shaw DE; Callahan J; Li Y; Yuan C; Bian C; Chen L; Furie B; Furie BC; Cines DB; Huang M
Science; 2006 Feb; 311(5761):656-9. PubMed ID: 16456079
[TBL] [Abstract][Full Text] [Related]
36. A structural mechanism of flavonoids in inhibiting serine proteases.
Xue G; Gong L; Yuan C; Xu M; Wang X; Jiang L; Huang M
Food Funct; 2017 Jul; 8(7):2437-2443. PubMed ID: 28644504
[TBL] [Abstract][Full Text] [Related]
37. The crystal structures of 3-TAPAP in complexes with the urokinase-type plasminogen activator and picrate.
Zesławska E; Jacob U; Stürzebecher J; Oleksyn BJ
Bioorg Med Chem Lett; 2006 Jan; 16(1):228-34. PubMed ID: 16202591
[TBL] [Abstract][Full Text] [Related]
38. Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition.
Jiang L; Oldenburg E; Kromann-Hansen T; Xu P; Jensen JK; Andreasen PA; Huang M
Biochim Biophys Acta Gen Subj; 2018 Sep; 1862(9):2017-2023. PubMed ID: 29959058
[TBL] [Abstract][Full Text] [Related]
39. Explaining urokinase type plasminogen activator inhibition by amino-5-hydroxybenzimidazole and two naphthamidine-based compounds through quantum biochemistry.
Solis-Calero C; Zanatta G; Pessoa CDÓ; Carvalho HF; Freire VN
Phys Chem Chem Phys; 2018 Sep; 20(35):22818-22830. PubMed ID: 30151512
[TBL] [Abstract][Full Text] [Related]
40. Engineering bidentate macromolecular inhibitors for trypsin and urokinase-type plasminogen activator.
Yang SQ; Craik CS
J Mol Biol; 1998 Jun; 279(4):1001-11. PubMed ID: 9642077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
